By Sriparna Roy (Reuters) -Eli Lilly agreed to buy Morphic Holding (NASDAQ:MORF) for $3.2 billion in cash, the companies said on ...

An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as it would be easier to manufacture and distribute globally.

The weight loss potential is not exactly there to match the likes of Eli Lilly’s tirzepatide or Novo ... author's opinion and should not be regarded as a buy or sell recommendation or investment ...

David Jagielski (Eli Lilly): A top pharma stock that I wouldn't hesitate to buy right now and hold for years is Eli Lilly. There is no shortage of reasons to be bullish on the stock, as it looks ...

Friday – BofA Securities maintained a Buy rating on Eli Lilly stock (NYSE:LLY), with a price target set at $997.00. With a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Eli Lilly has said it is seeking permission to build a new biopharmaceutical manufacturing facility in Ireland that will be used to produce active ingredients for its biologic medicines ...

Already developing a trio of incretin drugs for obesity, Eli Lilly ... said Lilly’s head of diabetes, obesity, and cardiometabolic research, Ruth Gimeno. Lilly aims to buy Versanis for up ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...